References: A practical guide to antiproteinuric drugs in dogs

Jul 30, 2013
By dvm360.com staff
1. Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981;241:F85-F93.
2. Brown SA, Finco DR, Crowell WA, et al. Single-nephron adaptations to partial renal ablation in the dog. Am J Physiol 1990;258:F495-503.
3. Hall JE, Brands MW, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol 1999;10 Suppl 12:S258-S265.
4. Tylicki L, Lizakowski S, Rutkowski B. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions. J Nephrol 2012;25:900-910.
5. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
6. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-1863.
7. Ruggenenti P, Pagano E, Tammuzzo L, et al. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int 2001;59:286-294.
8. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359-364.
9. Grauer GF, Greco DS, Getzy DM, et al. Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis. J Vet Intern Med 2000;14:526-533.
10. Lees GE, Brown SA, Elliott J, et al. Assessment and management of proteinuria in dogs and cats: 2004 ACVIM Forum Consensus Statement (small animal). J Vet Intern Med 2005;19:377-385.
11. Brown SA, Finco DR, Brown CA, et al. Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency. Am J Vet Res 2003;64:321-327.
12. Brown SA, Walton CL, Crawford P, et al. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993;43:1210-1218.
13. Tenhündfeld J, Wefstaedt P, Nolte IJ. A randomized controlled clinical trial of the use of benazepril and heparin for the treatment of chronic kidney disease in dogs. J Am Vet Med Assoc 2009;234:1031-1037.
14. DiBianco R. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors. Med Toxicol 1986;1:122-141.
15. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004;10:499-509.
16. Hamlin RL, Nakayama T. Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles. J Vet Intern Med 1998;12:93-95.
17. Lefebvre HP, Jeunesse E, Laroute V, et al. Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate. J Vet Intern Med 2006;20:499-507.
18. Lefebvre HP, Laroute V, Concordet D, et al. Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. J Vet Intern Med 1999;13:21-27.
19. Tocco DJ, deLuna FA, Duncan AE, et al. The physiological disposition and metabolism of enalapril maleate in laboratory animals. Drug Metab Dispos 1982;10:15-19.
20. Piepho RW. Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm 2000;57 Suppl 1:S3-S7.
21. Moesgaard SG, Pedersen LG, Teerlink T, et al. Neurohormonal and circulatory effects of short-term treatment with enalapril and quinapril in dogs with asymptomatic mitral regurgitation. J Vet Intern Med 2005;19:712-719.
22. Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007;18:1889-1898.
23. Schjoedt KJ, Astrup AS, Persson F, et al. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. Diabetologia 2009;52:46-49.
24. Toto RD, Mitchell HC, Lee HC, et al. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991;115:513-519.
25. Brooks DP, DePalma PD, Ruffolo RR. Effect of captopril and the nonpeptide angiotensin II antagonists, SK&F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis. J Pharmacol Exp Ther 1992;263:422-427.
26. Devoy MAB, Tomson CRV, Edmunds ME, et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 1992;232:493-498.
27. Schlesinger DP, Rubin SI. Potential adverse effects of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure. Compend Contin Educ Vet Pract 1994;16:275-283.
28. Jorde UP, Ennezat PV, Lisker J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101:844-846.
29. Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003;5:408-417.
30. Shiigai T, Shichiri M. Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001;37:477-483.
31. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. New Engl J Med 2004;351:1952-1961.
32. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-867.
33. Bakris G, Burgess E, Weir M, et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008;74:364-369.
34. Christ DD, Wong PC, Wong YN, et al. The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. J Pharmacol Exp Ther 1994;268:1199-1205.
35. Heller J, Kramer HJ, Horacek V. Comparative effects of the angiotensin II receptor blocker EXP 3174 and of the angiotensin-converting enzyme inhibitor captopril on renal glomerular hemodynamics in the dog. Kidney Blood Press Res 1997;20:391-397.
36. Wu MY, Ma XJ, Yang C, et al. Effects of allisartan, a new AT(1) receptor blocker, on blood pressure and end-organ damage in hypertensive animals. Acta Pharmacol Sin 2009;30:307-313.